| Ytd | -33.83% | |
| 1y | -90.76% |
| Open | 0.54 | Prev Close | 0.53 | Low | 0.51 | High | 0.54 | Mkt Cap | 51.12M |
| Vol | 287.18K | Avg Vol | 2.66M | EPS | 0.02 | P/E | 26.07 | Forward P/E | -4.33 |
| Beta | 0.54 | Short Ratio | 2.66 | Inst. Own | 63.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.51 | 200-d Avg | 0.73 | 1yr Est | 21.29 |
ATYR News
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechn
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst cons
Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvem
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvem
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's afte
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst cons
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting wit
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biote
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoido
aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback.
aTyr Pharma (NASDAQ: ATYR) CEO Sanjay Shukla outlined the company's strategy to develop new therapie
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.14) per share which beat the analyst cons
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-F
aTyr Pharma, Inc. (NASDAQ: ATYR - Get Free Report) shares were down 2.1% during mid-day trading on T
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Compan
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biot
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path f
AUSTIN, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company
aTyr Pharma, Inc. (NASDAQ: ATYR - Get Free Report) was the recipient of a significant drop in short
AUSTIN, Texas and DES MOINES, Iowa, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insuranc
SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential derivative
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential derivat
NEW YORK , Dec. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remi
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareh
